DX 107
Alternative Names: DX-107Latest Information Update: 24 Feb 2026
At a glance
- Originator Delonix Bioworks
- Class Bacterial vaccines; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Research Gonorrhoea
Most Recent Events
- 17 Feb 2026 DX 107 is available for licensing as of 17 Feb 2026. https://delonixbio.com/pipeline.html
- 17 Feb 2026 Early research in Gonorrhoea in China (Parenteral) (Delonix Bioworks pipeline, February 2026)